@ Whalatane...I agree with you regarding MRC to an extent.
The issue is not that MRC has a contrary opinion to those of Amarin bulls. It is that he has an 'agenda' with regards to Amarin.
When I first read his stuff, I am saying to myself that no way in hell is this analysis coming from a legitimate analyst. Legit analysts don't give a flying **ck if you agree with them or not. They do their analysis and move on to their next project. MRC is absolutely obsessed with AMRN and AMRN alone (even though he has mentioned on the website a few other stocks in passing to denigrate).
His original disclaimers as to not disclosing the identity of those individuals behind MRC do not pass muster. MRC has to be a front for some other players.
MRC has tunnel vision directed solely at AMRN. Here are a few lines taken 5 minutes ago off of the MRC website.
quotes:
_______________________________________________________________________
Quick but thorough analysis of healthcare plays that have recently experienced a binary event, but are "hung up" in massive trading volume and unable to "break out." Notable examples being CPXX at $7, AMRN at $9, AGRX at $1.20, RETA ay $140, and KRTX at $30.
AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP
*For the following report: we will send a PDF file containing the report to the email address you us..
$8,500.00
Examples of the depth and quality of our research may found in our citizen petitions on Amarin Corp., and comment to the public docket regarding the Advisory Committee meeting to discuss the Vascepa sNDA, with PDFs located here(1), here(2), here(3), and here(4).
________________________________________________________________________
When in the world was AMRN last trading at $9 and 'unable to break out'?
The above is just baffling for a company that purports to be an analytical research firm. Who the hell do they cover other than AMRN, and every utterance coming forth is a hard bash against AMRN.
Screw them and whomever is involved.
Cheers to AMRN longs!
Flubber
